Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) Short Interest Update
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 86,300 shares, a growth of 39.6% from the August 30th total of 61,800 shares. Based on an average daily trading volume, of 3,700,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.4% of the shares of the company are short sold.
NASDAQ:SNNA traded down $0.03 on Monday, reaching $0.22. 1,758,006 shares of the company’s stock were exchanged, compared to its average volume of 1,433,158. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.43 and a quick ratio of 2.43. The firm has a market cap of $6.91 million, a price-to-earnings ratio of -0.06 and a beta of 2.67. Sienna Biopharmaceuticals has a 52 week low of $0.10 and a 52 week high of $12.97. The stock has a fifty day simple moving average of $0.47 and a 200-day simple moving average of $1.12.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last issued its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.16. As a group, sell-side analysts predict that Sienna Biopharmaceuticals will post -3.1 EPS for the current year.
A number of analysts recently issued reports on the stock. ValuEngine upgraded shares of Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. BMO Capital Markets decreased their price objective on shares of Sienna Biopharmaceuticals to $3.00 and set an “outperform” rating for the company in a report on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $17.00.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Recommended Story: What is the 52-week high/low?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.